TREATMENT ISSUES IN TYPE 1 DIABETES - STRATEGIES FOR INSULIN USE

Abstract
The topic of approaches to insulin treatment is of great importance in the management of type 1 diabetes, and has growing applicability to all forms of diabetes as we strive for optimized glycemia. Strategies for insulin use for persons with type 1 diabetes involve focus on overall glycemic management and use of the new short-acting meal-related and long-acting basal insulin analogs. This article is based on a previous review. (1)

Key words
Diabetes tipo 1, detemir insulina, glargine insulina, lispro insulina, aspartato insulina

Bibliografía del artículo

1. Bloomgarden ZT. Treatment Issues in Type 1 Diabetes. Diabetes Care 2002;25:230-236
2. Woodworth JR, Howey DC Bowsher RR. Establishment of time-action profiles for regular and NPH insulin using pharmacodynamic modeling. Diabetes Care1994;17:64-69
3. Danowski TS, Sunder JH. Jet injection of insulin during self-monitoring of blood glucose. Diabetes Care 1978 1: 27-33.
4. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 18: 361-376.
5. Riccio A, Avogaro A, Valerio A, Zappella A, Tiengo A, Del Prato S. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin. Diabetes Care, 17:535-540, 1994
6. Zinman B, Ross S, Campos RV, Strack T .Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. A double-blind randomized prospective trial. Diabetes Care 22:603-608, 1999
7. Porcellati et al. (8-LB(Abstracts of the 61st Annual Meeting of the American Diabetes Association, Diabetes 50 [Suppl. 2]:1-A649)
8. Rosenstock J, Park G, Zimmerman J.Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care, 23: 1137-1142, 2000
9. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23: 1666-1671, 2000.
10. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 23: 639-643, 2000.
11. Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, Dunger DIABETIC. Randomized Cross-Over Trial of Insulin Glargine Plus Lispro or NPH Insulin Plus Regular Human Insulin in Adolescents With Type 1 Diabetes on Intensive Insulin Regimens Diabetes Care 26: 799-804, 2003.
12. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the Soluble Basal Insulin Analog Insulin Detemir With NPH Insulin: A randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy Diabetes Care 24: 296-301, 2001
13. Vague P, Selam JL, Skeie S, De Leeuw I, Elte JWF, Haahr H, Kristensen A, Draeger E. Insulin Detemir Is Associated With More Predictable Glycemic Control and Reduced Risk of Hypoglycemia Than NPH Insulin in Patients With Type 1 Diabetes on a Basal-Bolus Regimen With Premeal Insulin Aspart Diabetes Care 26: 590-596, 2003
14. Postprandial Blood Glucose Diabetes Care 24:775-778, 2001
15. Bastyr EJ, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, Robertson KE. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 23: 1236-1241, 2001
16. de Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, Evans AT. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med. 1995;333:1237-41
17. Ciofetta M, Lalli C, Del Sindaco P, Torlone E, Pampanelli S, Mauro L, Chiara DL, Brunetti P, Bolli GB.Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care, 22:795-800, 1999
18. Home PD, Lindholm A, Hylleberg B, Round P.Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care, 21:1904-1909, 1998
19. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care, 23:583-588, 2000
20. Heller SR, Amiel SA, Mansell P.Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. Diabetes Care, 22:1607-1611, 1999
21. Brunelle BL, Llewelyn J, Anderson JH, Gale EA, Koivisto VA.Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care, 21:1726-1731, 1998
22. Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini MG, Bartocci L, Brunetti P, Bolli GB. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime Diabetes Care 22: 468-477, 1999

Autoevaluación